Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inovio progresses on RRP treatment, faces trial challenges and opportunities

Inovio Pharmaceuticals is making progress on INO-3107 and other pipeline candidates while managing financials and strategic trial design.
The company faces challenges in trial design, patient representation, and regulatory requirements but sees opportunities in market access and patient outcomes.
Overall, Inovio remains focused on advancing DNA medicine and delivering on key objectives for the benefit of patients.
Analysts' questions and executive responses indicate a thorough approach to addressing concerns and ensuring trial success.

INOVIO Pharmaceuticals reports solid Q3 performance and eyes global expansion

INOVIO Pharmaceuticals showcased financial stability, regulatory progress, and scientific advancements in Q3 2024, positioning the company for future growth.
Despite financial challenges and potential hurdles, the company's strong financial position, robust pipeline, and strategic commercial planning offer opportunities for success.
Addressing challenges like financial losses, regulatory complexities, and market competitiveness will be crucial for maximizing opportunities and achieving long-term growth.
By leveraging strengths, navigating challenges, and capitalizing on opportunities, INOVIO Pharmaceuticals aims to drive innovation, secure regulatory approvals, and capture market share.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

U.S. stocks traded mixed toward the end of trading, with the S&P 500 edging lower on Friday.

Gold Down Over 1%; Inovio Pharmaceuticals Shares Plummet

PLYMOUTH MEETING, Pa. , Dec. 13, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock and accompanying warrants to purchase 10,000,000 shares of its common stock at an exercise price of $3.76 per share of common stock, at a combined public offering price of $3.00 per share of common stock and accompanying warrant.

INOVIO Announces Pricing of $30 Million Public Offering

PLYMOUTH MEETING, Pa. , Dec. 12, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock, in an underwritten public offering.

INOVIO Announces Proposed Public Offering

Data from a retrospective trial evaluating the longer-term benefit of INO-3107 to patients with Recurrent Respiratory Papillomatosis (RRP) involved in a Phase 1/2 trial showed the number of patients who met the criteria for a Complete Response (CR) increased to 50% by the end of year 2 and to 54% in year 3, compared to 28% by the end of the initial 52-week trial 95% of patients in the retrospective trial (RRP-002) maintained or enhanced their original Overall Response Rate (ORR) reported in the Phase 1/2 trial (RRP-001) by the end of year 2; 86% of patients maintained or enhanced ORR into year 3 New durability data will help inform re-dosing strategy focused on long-term elimination or reduction in the need for surgery to treat RRP disease INOVIO plans to present data at future scientific conferences and submit for publication in peer-reviewed journals PLYMOUTH MEETING, Pa. , Dec. 3, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced data from a retrospective trial showing that the number of RRP patients meeting the criteria for a Complete Response increased to 50% by the end of the second year following initial treatment with INO-3107 in a previously reported Phase 1/2 52-week trial where the Complete Response rate was 28%.

New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial

PLYMOUTH MEETING, Pa. , Nov. 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").

INOVIO Reports Inducement Grant Under Inducement Plan

AstraZeneca

BioNTech SE

GlaxoSmithKline

Merck

Sanofi

Valneva SE

Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services.

European And US Vaccine Stocks Are Under Pressure - Here's WHy

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q3 2024 Earnings Call Transcript November 14, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of IR Jacqui Shea - President and CEO Mike Sumner - CMO Steve Egge - CCO Peter Kies - CFO Matthew Morrow - VP of Translational Sciences Conference Call Participants Jay Olson - Oppenheimer Roy Buchanan - Citizens JMP Sudan Loganathan - Stephens Liang Cheng - Jefferies Operator Good afternoon, ladies and gentlemen, and welcome to the Inovio Third Quarter 2024 Financial Results Conference Call. At this time, all lines are in a listen-only mode.

Inovio Pharmaceuticals, Inc. (INO) Q3 2024 Earnings Call Transcript

New immunology data for INO-3107 supporting proposed mechanism of action presented at several recent conferences  Data showed ability of INO-3107 to induce an antigen-specific cytotoxic T cell response against HPV-6 and HPV-11 and drive recruitment of T cells into airway tissues and papilloma Data showed INO-3107 induced expansion of new clonal T cells that infiltrate airway tissues and correspond with reduction of surgeries for RRP patients observed in Phase 1/2 trial Continued progress on preparing regulatory submissions for INO-3107 All non-device BLA modules on track for completion by end of 2024 BLA submission remains targeted for mid-2025 PLYMOUTH MEETING, Pa. , Nov. 14, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the third quarter of 2024 and provided an update on recent company developments.

INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights

New immunology data shows INO-3107 induced an expansion of new clonal T cells in blood that were not detectable prior to treatment New clonal T cells in the blood travelled to papilloma and airway tissues and generated an inflammatory and anti-viral response consistent with a reduced need for surgeries for patients with recurrent respiratory papillomatosis (RRP) caused by HPV-6 and HPV-11 Data supporting mechanism of action for INO-3107 to be presented at 36th International Papillomavirus Conference in Edinburgh, UK PLYMOUTH MEETING, Pa. , Nov. 13, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced new immunology data that supports the clinical activity of its lead product candidate, INO-3107, that was previously observed in a Phase 1/2 trial of RRP patients.

Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial

PLYMOUTH MEETING, Pa. , Nov. 6, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conferences: 36th International Papillomavirus Conference (Edinburgh, UK; November 12-15) Presentation and poster by Dr. Matthew Morrow, VP of Translational Sciences Abstract Title: Treatment of recurrent respiratory papillomatosis with INO-3107 induces significant enrichment in hallmark interferon alpha, interferon gamma and inflammatory molecular signatures in papilloma tissue of responders Poster by Dr. Jeffrey Skolnik, SVP of Clinical Development Abstract Title: Clinical response to INO-3107 treatment for recurrent respiratory papillomatosis is associated with CD4 and CD8 T-Cell activity and cytotoxicity in patient airways Vaccines Summit (Boston, MA; November 13-15) Keynote presentation by Dr. Dave Liebowitz, SVP Early-Stage Clinical Development Abstract Title: DNA Medicines Vaccine Platform for both Prophylactic and Therapeutic Applications: Case Studies in Ebola and Recurrent Respiratory Papillomatosis Abstracts from these conferences will be made available on INOVIO's website following each presentation.

INOVIO to Present at Upcoming Scientific Conferences

PLYMOUTH MEETING, Pa. , Nov. 6, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that third quarter 2024 financial results will be released after the market close on November 14, 2024.

INOVIO to Report Third Quarter 2024 Financial Results on November 14, 2024

American Association for Cancer Research (AACR) Special Conference: Tumor Immunology and Immunotherapy : New immunology data showed ability of INO-3107 to induce an antigen-specific T cell response against HPV-6 and HPV-11 and drive recruitment of T cells into airway tissues and papilloma International Society of Vaccines Conference : Full safety and efficacy data from Phase 1/2 clinical study in patients with Recurrent Respiratory Papillomatosis (RRP) indicated that INO-3107 was well tolerated and immunogenic; 81% of patients in the trial required fewer surgeries post-treatment when compared to baseline PLYMOUTH MEETING, Pa. , Oct. 21, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the presentation of new data at scientific conferences for its lead candidate, INO-3107, for which the company is preparing a Biologics License Application for targeted submission in mid-2025 under the U.S. Food and Drug Administration's Accelerated Approval Pathway Program.

INOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRP

Inovio (INO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Inovio (INO) Surges 6.8%: Is This an Indication of Further Gains?

PLYMOUTH MEETING, Pa. , Oct. 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made equity grants to certain employees under its 2022 Inducement Plan (the "Inducement Plan").

INOVIO Reports Inducement Grants Under Inducement Plan

PLYMOUTH MEETING, Pa. , Sept. 17, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conference: World Congress of Electroporation Oral Presentation by Trevor Smith, VP of Preclinical R&D at INOVIOAbstract Title: Development of in vivo-launched synthetic DNA-encoded antibodies employing CELLECTRA® electroporation technology Date and Time: September 18, 2024, 3:20pm – 3:35pm CET Location: Rome, Italy The abstract from the conference will be made available on INOVIO's website following the data presentation.

INOVIO to Present at Upcoming Scientific Conference

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of Investor Relations Jacqueline Shea - President & Chief Executive Officer Steve Egge - Chief Commercial Officer Michael Sumner - Chief Medical Officer Peter Kies - Chief Financial Officer Conference Call Participants Anish Nikhanj - RBC Capital Markets Roy Buchanan - Citizens JMP Jay Olson - Oppenheimer Sudan Loganathan - Stephens Yi Chen - H.C. Wainwright Operator Good afternoon ladies and gentlemen and welcome to the Inovio Second Quarter 2024 Financial Results Conference Call.

Inovio Pharmaceuticals, Inc. (INO) Q2 2024 Earnings Call Transcript

PLYMOUTH MEETING, Pa. , Aug. 8, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the second quarter of 2024 and provided an update on recent company developments.

INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Data reviewed complies with standards that would be  used to evaluate an EU Marketing Authorization Application PLYMOUTH MEETING, Pa. , July 25, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the European Medicines Agency's Committee for Advanced Therapies (CAT) has certified the quality and non-clinical data for INO-3107, INOVIO's lead candidate for the treatment of Recurrent Respiratory Papillomatosis (RRP).

Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107

PLYMOUTH MEETING, Pa. , July 25, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that second quarter 2024 financial results will be released after the market close on August 8, 2024.

INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024

Inovio (INO) soars 19% as its lead candidate, INO-3107, receives the innovative medicine tag under the U.K.'s Innovative Licensing and Access Pathway to treat recurrent respiratory papillomatosis.

Inovio (INO) Up as Lead Drug Gets Innovative Medicine Tag in UK

Inovio (INO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Inovio (INO) Soars 19.0%: Is Further Upside Left in the Stock?

Award recognizes the potential for INO-3107 to be the first therapeutic option in the United Kingdom for patients suffering from Recurrent Respiratory Papillomatosis (RRP) PLYMOUTH MEETING, Pa. , July 11, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that its lead DNA medicine candidate, INO-3107, has been designated an innovative medicine as part of the U.K.'s Innovative Licensing and Access Pathway (ILAP).

INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway

Mr. Egge brings over 25 years of biopharmaceutical experience building commercial organizations and successfully launching novel therapeutic products INOVIO poised to become a commercial-stage company with plans to submit a Biologics License Application for INO-3107 in second half of 2024 under U.S. Food and Drug Administration's Accelerated Approval Pathway PLYMOUTH MEETING, Pa. , July 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the appointment of Steven Egge as Chief Commercial Officer.

INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer

PLYMOUTH MEETING, Pa. , July 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced its inclusion in the Russell 2000® Index as part of the annual reconstitution of the Russell stock indexes.

INOVIO Added to Russell 2000® Index Effective July 1, 2024

PLYMOUTH MEETING, Pa. , June 4, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that INOVIO's President and CEO, Dr. Jacqueline Shea, and Chief Medical Officer, Dr. Michael Sumner will participate in a virtual fireside chat hosted by Sudan Loganathan, Ph.D.

News for Inovio Pharmaceuticals Stock (INO)